Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.

Date publication

juillet 2020

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr VINCENT Julie , Dr BENGRINE-LEFEVRE Leila , Dr FUMET Jean-David , Dr HENNEQUIN Audrey

Tous les auteurs :
Fumet JD, Vincent J, Bengrine L, Hennequin A, Granconato L, Palmier R, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32620645

Résumé

The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX.

Mots clés

Pancreatic cancer, capecitabine, chemotherapy, cisplatin, docetaxel, gemcitabine

Référence

Anticancer Res.. 2020 Jul;40(7):4011-4015